Clinerion Ltd Contact Details:
Main address: Margarethenstrasse 47 4053 Basel, Switzerland ,
Tel:+41 61 865 60 60 , E-mail: info(at) Website:

Clinerion Patient Network Explorer

Clinerion Patient Network Explorer

Optimized study design, precise site selection and faster patient search and identification for clinical research - in real time.

Clinerion Cookie Policy

Welcome to the Clinerion website. This website uses cookies. These cookies are used on your browser to understand how you are using our website. Using this website means you agree to our use of cookies. If you prefer not to have these cookies on your device, we advise you to disable them in your web browser settings. You accept the use of cookies by accepting this notice. You can read more details via our Privacy Policy page.

Privacy Policy page >

Interview: Patient Centricity & RWE

Keyla Deucher (PharmD, MBA,MsC), is Director at BioServ SMO, and Clinical Research Manager at the Research Unit of Clinica Hospital Sao Vicente de Paulo, in Passo Fundo, Brazil.

22.08.2019, Basel, Switzerland

Keyla Deucher

Clinerion: Our whole industry seems to focus more and more on ‘Patient Centricity’. What does this term really mean for you, practically in your daily job?

Keyla Deucher: I think Patient Centricity is the humanization of clinical care in human research. Patient Centricity wants clinical trials to focus on the patient’s experience and needs. Our challenge as Clinical Research professionals is to fulfil our scientific role, while not forgetting to involve patients as much as we can. [...]



Patients are being involved more and more, even at the early stages of clinical trials: many protocols are now designed using patient experience, and rely on real-world data more than before - which is an interesting shift, as we know patient-focused trials are proven to be more successful.

As healthcare professionals involved in trials, our job is to increase patients’ autonomy and engagement. In our daily activity, this means we need to talk more to the patients and inform them better, to make them understand their role in the trial and improve their experience. The more they know, the more active and engaged they will become, and the more successful the trial will be.

Clinerion: How does "Real World Data" support Clinical Trials?

Keyla Deucher: This is another interesting part of this “Patient Centricity” shift: using real-world data during the protocol design phase will support more consistency in terms of the design itself, and better outcomes. For example, many clinical trials are performed in Brazil, but the way these trials are designed is based on the needs of European and American patients - which doesn’t necessarily reflect the reality in Brazil. That’s where there’s clear room for improvement, and that’s why real world data should be used to design trial protocols.

Clinerion: How do you think Clinical Trials will evolve over the next few years? 

I think real world evidence will be generated more and more in the future to speed up the clinical trials process, and to improve trials and patient outcomes. We’ll use information that is already available, and that patients accept to share. Artificial Intelligence is also one of the important ongoing changes in clinical trials, as it’s a very useful tool to support real world evidence. The future for both pharma professionals AND patients will be: more and more data becoming available and exploitable, the systematic use of this real-world data, and patients becoming more and more involved at all steps of the trials.

Looking for "the right patient, for the right trial, at the right time"?

Contact us.

Personal Data Protection Statement

The information you provide allows us to provide you with information and updates on Clinerion’s products and services (the purpose). By submitting your details in this form, you give explicit consent that your personal details may be used for this and only this purpose by Clinerion.

Clinerion, as the data controller and processor, will maintain the data for as long as the data is required for the purposes mentioned above, or until you withdraw consent as stated below. Personal data are not kept longer than necessary and are processed in a manner that ensures appropriate security and confidentiality, including for preventing unauthorized access to or use of personal data and the equipment used for the processing.

We will not sell or give away any personal information that you provide and only use it for the purposes stated above. You may request to view, correct, or delete your data in Clinerion’s database or withdraw consent by contacting Please note that withdrawal of consent shall not affect the lawfulness of Clinerion’s use of your personal data for the purposes mentioned above before withdrawal of consent.

The legal address of Clinerion: Clinerion Ltd, Elisabethenanlage 11, 4051 Basel, Switzerland. e-Mail address

News / Events / Webinars